Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Rating of “Hold” by Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given an average recommendation of “Hold” by the thirteen research firms that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $42.09.

Several brokerages have recently issued reports on KYMR. B. Riley upped their target price on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday. Oppenheimer reiterated an “outperform” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research note on Monday, June 17th.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $39.00 on Friday. The stock has a market cap of $2.39 billion, a PE ratio of -15.54 and a beta of 2.22. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $45.31. The firm’s 50-day simple moving average is $33.84 and its two-hundred day simple moving average is $34.66.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, May 2nd. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.04. The firm had revenue of $10.30 million for the quarter, compared to the consensus estimate of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. The business’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. Equities research analysts predict that Kymera Therapeutics will post -2.86 EPS for the current year.

Insider Activity at Kymera Therapeutics

In related news, Director Bruce Booth sold 16,740 shares of the stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total transaction of $593,433.00. Following the transaction, the director now owns 803,792 shares in the company, valued at $28,494,426.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Kymera Therapeutics news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce Booth sold 16,740 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $35.45, for a total transaction of $593,433.00. Following the sale, the director now directly owns 803,792 shares of the company’s stock, valued at $28,494,426.40. The disclosure for this sale can be found here. Insiders have sold a total of 479,200 shares of company stock worth $18,219,660 over the last quarter. Company insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new stake in Kymera Therapeutics during the fourth quarter valued at approximately $78,000. Comerica Bank increased its stake in shares of Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after purchasing an additional 295 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Kymera Therapeutics in the first quarter worth $207,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock worth $164,000 after purchasing an additional 5,002 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.